• Blog
  • Pricing
  • Contact
  • FAQ
Sign InSign Up
AI Agent for Financial MarketsAsk anything. Our AI Agent brings real-time data and full market coverage.Open chat
MarketsStocksCryptoForexCommoditiesCalendarInsiders
BIOC

BIOC

Biocept, Inc.

NASDAQHealthcareMedical - Diagnostics & ResearchUS

USD0.43

+0.00 (+0.00%)

Company Profile

CEO

Darrell Taylor

IPO Date

2014-02-05

Sector

Healthcare

Industry

Medical - Diagnostics & Research

Exchange

NASDAQ

Country

US

Market Metrics

Open

$0.49

Prev. Close

$0.43

Day Low

$0.43

Day High

$0.49

52W Low

$0.43

52W High

$0.49

Market Cap

$0.00B

Volume

0.57M

OverviewFinancialsRatingsInsidersSentimentsChart Patterns
News SentimentBullish

Articles

10

Avg Positive

56.2%

Avg Negative

3.0%

Avg Neutral

40.5%

News Feed

Investors React Positively To Study Data Of Biocept's Cerebrospinal Fluid Assay

Benzinga·8/19/2021·↑ positive

Biocept says a study of its cerebrospinal fluid assay CNSide shows potential use for cancer treatment

Proactive Investors·8/19/2021·↑ positive

Biocept Shares Increase Over 20% Pre-Market: Why It Happened

Pulse2·8/19/2021·↑ positive

Biocept's CNSide Assay Identifies Tumor Cells and Actionable Treatment Biomarkers from Cerebrospinal Fluid in Patients with Metastatic Non-Small Cell Lung Cancer

Business Wire·8/19/2021·↑ positive

Biocept reports profitability for the first half on back of increased COVID-19 testing

Proactive Investors·8/17/2021·↑ positive

Biocept, Inc. (BIOC) CEO Michael Nall on Q2 2021 Results - Earnings Call Transcript

Seeking Alpha·8/16/2021·↓ negative

Biocept appoints David Karlander as senior vice president of Commercial Operations

Proactive Investors·8/3/2021·↑ positive

Biocept Names David Karlander as Senior Vice President of Commercial Operations

Business Wire·8/3/2021·↓ negative

Medicare Issues Coverage Determination For Biocept's Target Selector Assay For Breast Cancer

Benzinga·7/21/2021·↑ positive

Biocept wins approval for expanded Medicare coverage for its Target Selector assay to detect cancer biomarkers

Proactive Investors·7/21/2021·↑ positive